论文部分内容阅读
目的探讨并评价福辛普利治疗轻度、中度原发性高血压患者的临床治疗效果和安全性。方法选取2013年6月至2014年6月在广西百色市右江民族医学院附属医院药治疗的100例轻度、中度原发性高血压患者作为研究对象,按照随机分配的方式将其分为对照组和观察组,各50例。对照组患者服用苯那普利进行治疗,观察组患者服用福辛普利进行治疗。对两组患者进行为期4周的观察,观察患者的血压、心率以及药物使用后的不良反应发生情况。结果治疗后,两组患者血压均有明显改善(P<0.05),而两组患者的心率及治疗总有效率、不良反应发生情况差异均无统计学意义(均P>0.05);但观察组患者咳嗽发生率低于对照组(P<0.05)。结论福辛普利治疗轻度、中度原发性高血压,不仅具有较为显著的疗效,还具有较高的安全性。与其他血管紧张素转化酶抑制剂相比,福辛普利能有效减少患者用药后咳嗽的发生率,从而确保患者能够继续接受治疗。
Objective To investigate and evaluate the clinical efficacy and safety of fosinopril in patients with mild to moderate essential hypertension. Methods From June 2013 to June 2014, 100 patients with mild to moderate essential hypertension treated with drugs in the Affiliated Hospital of Youjiang Medical College, Baise City, Guangxi Zhuang Autonomous Region were selected as the research subjects. According to the method of random allocation, For the control group and observation group, 50 cases each. Patients in the control group were treated with benazepril, and patients in the observation group were treated with fosinopril. The two groups of patients for a period of 4 weeks of observation, observation of patients with blood pressure, heart rate and adverse reactions after drug use. Results After treatment, blood pressure was significantly improved in both groups (P <0.05), while there was no significant difference in heart rate, total effective rate of treatment and incidence of adverse reactions between the two groups (all P> 0.05) The incidence of cough in patients was lower than that in controls (P <0.05). Conclusion Fosinopril treatment of mild to moderate essential hypertension, not only has a more significant effect, but also has high safety. Compared with other angiotensin-converting enzyme inhibitors, fosinopril can effectively reduce the incidence of cough after medication, to ensure that patients can continue to receive treatment.